IRIS
SCARTOZZI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.475
EU - Europa 1.107
AS - Asia 914
SA - Sud America 347
AF - Africa 70
Continente sconosciuto - Info sul continente non disponibili 4
Totale 4.917
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.448
SG - Singapore 347
BR - Brasile 283
UA - Ucraina 189
CN - Cina 182
IT - Italia 165
SE - Svezia 141
RU - Federazione Russa 124
DE - Germania 121
IE - Irlanda 121
TR - Turchia 106
VN - Vietnam 92
FI - Finlandia 77
HK - Hong Kong 72
DK - Danimarca 68
GB - Regno Unito 45
CI - Costa d'Avorio 39
KR - Corea 37
FR - Francia 25
JP - Giappone 23
IN - India 21
AR - Argentina 19
MA - Marocco 18
CA - Canada 13
BD - Bangladesh 11
EC - Ecuador 11
MX - Messico 11
CO - Colombia 9
PL - Polonia 7
PY - Paraguay 7
ID - Indonesia 6
VE - Venezuela 6
ZA - Sudafrica 6
BE - Belgio 5
ES - Italia 5
NL - Olanda 5
CL - Cile 4
CZ - Repubblica Ceca 4
EU - Europa 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
IQ - Iraq 3
KE - Kenya 3
PE - Perù 3
AZ - Azerbaigian 2
DZ - Algeria 2
RS - Serbia 2
SA - Arabia Saudita 2
AT - Austria 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
EG - Egitto 1
HN - Honduras 1
IM - Isola di Man 1
IR - Iran 1
JM - Giamaica 1
KG - Kirghizistan 1
LB - Libano 1
LT - Lituania 1
MM - Myanmar 1
OM - Oman 1
PK - Pakistan 1
TN - Tunisia 1
UZ - Uzbekistan 1
Totale 4.917
Salva come PNG Salva come JPEG
Città #
Ashburn 323
Singapore 231
Fairfield 210
Jacksonville 209
Chandler 199
Wilmington 120
Dublin 119
Dallas 113
Des Moines 99
Boardman 96
Woodbridge 95
New York 83
Seattle 77
Hong Kong 72
Houston 72
Beijing 57
Cambridge 50
Centro 49
Lawrence 47
Princeton 47
Los Angeles 46
The Dalles 45
San Mateo 43
Ann Arbor 42
Abidjan 38
Munich 34
Ho Chi Minh City 28
Turin 28
Moscow 25
Helsinki 23
São Paulo 23
San Diego 22
Hanoi 21
Turku 19
Tokyo 17
London 16
Buffalo 15
Hefei 14
Chicago 12
Porto Alegre 11
Washington 11
Pune 9
Rio de Janeiro 9
Columbus 8
Curitiba 8
Haiphong 8
Atlanta 6
Belo Horizonte 6
Brasília 6
Chennai 6
Denver 6
Frankfurt am Main 6
Guayaquil 6
Kilburn 6
Norwalk 6
Shanghai 6
Warsaw 6
Ancona 5
Campinas 5
Fortaleza 5
Johannesburg 5
Orem 5
Rome 5
Salvador 5
San Francisco 5
Santa Clara 5
Stockholm 5
Thái Nguyên 5
Toronto 5
Wuhan 5
Bogotá 4
Brussels 4
Cagliari 4
Izmir 4
Montevideo 4
Olomouc 4
Salt Lake City 4
Ankara 3
Brooklyn 3
Carney 3
Dhaka 3
Goiânia 3
Guarulhos 3
Istanbul 3
Jiaxing 3
Joinville 3
Kagoya 3
Lima 3
Miami 3
Montreal 3
New Bedfont 3
Petrópolis 3
Phoenix 3
Poplar 3
Redwood City 3
San Jose 3
Santo André 3
Sorocaba 3
St Petersburg 3
Viamão 3
Totale 3.171
Salva come PNG Salva come JPEG
Nome #
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 174
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 148
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 143
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 141
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 138
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 137
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 135
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 130
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 125
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 123
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 120
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 119
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 118
BRAF-mutant colorectal cancer, a different breed evolving 117
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 115
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 113
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 112
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 110
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 110
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 108
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 108
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 105
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 105
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 105
Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. 103
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 102
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 101
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 100
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 98
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 97
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. 97
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? 94
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 91
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 91
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 91
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 89
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 85
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. 84
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 82
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 81
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma 78
Tracking the 2015 gastrointestinal cancers symposium: Bridging cancer biology to clinical gastrointestinal oncology 76
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 76
Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? 72
Selected news from the 2014 Genitourinary Cancers Symposium: Translating novel strategies into clinical practice 69
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 66
Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. Anticancer Res. 2013 Oct;33(10):4611-7 65
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 15
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 12
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 12
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 8
null 7
null 7
null 6
null 2
Totale 5.016
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.890
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.890
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021377 0 0 0 0 0 40 46 65 50 78 52 46
2021/2022364 36 66 10 2 1 28 15 21 24 62 42 57
2022/2023745 52 93 51 42 37 165 0 38 177 5 75 10
2023/2024408 66 8 37 42 62 114 7 12 0 7 10 43
2024/2025866 122 67 15 13 39 41 104 34 162 66 99 104
2025/20261.185 168 211 154 283 337 32 0 0 0 0 0 0
Totale 5.016